PS
BTAI

Portfolio Strategies’s BioXcel Therapeutics BTAI Stock Holding History

Portfolio Strategies’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7K Buy
16,831
+4,653
+38% +$5.45K ﹤0.01% 81
2026
Q1 		$16.3K Hold
12,178
– – ﹤0.01% 74
2025
Q4 		$19.5K Buy
+12,178
New +$25.1K ﹤0.01% 59

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Portfolio Strategies's BTAI Position: Q2 2026 in Review

Portfolio Strategies increased its BioXcel Therapeutics (BTAI) stake by 38% in Q2 2026, buying an estimated $5.45K and bringing the position to 16,831 shares worth $23.7K. The position accounts for ﹤0.01% of the portfolio, ranked #81.

Portfolio Strategies first reported a position in BTAI in Q4 2025 and has held it in 3 quarters since. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Portfolio Strategies held 16,831 shares of BioXcel Therapeutics worth $23.7K as of Q2 2026.
  • Portfolio Strategies bought 4,653 BioXcel Therapeutics shares in Q2 2026, an estimated $5.45K.
  • BioXcel Therapeutics made up ﹤0.01% of Portfolio Strategies's portfolio in Q2 2026, its #81 holding.
  • Portfolio Strategies first reported a position in BioXcel Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Portfolio Strategies's 13F filing for Q2 2026, filed 10 Aug 2026.